1
|
Decroos A, Cheminant M, Bruneau J, Carras S, Parinet V, Pelletier L, Lacroix L, Martin N, Giustiniani J, Lhermitte L, Asnafi V, Battistella M, Lemonnier F, De Leval L, Sicard H, Bonnafous C, Gauthier L, Genestier L, Caruso S, Gaulard P, Hermine O, Ortonne N. KIR3DL2 may represent a novel therapeutic target in aggressive systemic peripheral T-cell lymphoma. Haematologica 2023; 108:2830-2836. [PMID: 37165836 PMCID: PMC10542838 DOI: 10.3324/haematol.2022.282220] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Accepted: 05/03/2023] [Indexed: 05/12/2023] Open
Affiliation(s)
- Amandine Decroos
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Morgane Cheminant
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP Clinical Hematology, F-75015, Paris
| | - Julie Bruneau
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP, Department of Pathology, F-75015, Paris
| | - Sylvain Carras
- Institute for Advanced Biosciences, "Translational Epigenetics" team, UMR 1209/CNRS 5309, La Tronche
| | - Vincent Parinet
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Laura Pelletier
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Laetitia Lacroix
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris
| | - Nadine Martin
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Jérôme Giustiniani
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil
| | - Ludovic Lhermitte
- Université de Paris, Institut Necker-Enfants Malades, Laboratory of Onco-Hematology, APHP, INSERM UMR 1151, Paris
| | - Vahid Asnafi
- Université de Paris, Institut Necker-Enfants Malades, Laboratory of Onco-Hematology, APHP, INSERM UMR 1151, Paris
| | - Maxime Battistella
- Université Paris Cité ; INSERM U976 ; AP-HP, Department of Pathology, Saint-Louis hospital, F-75010 Paris
| | - François Lemonnier
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, Clinical Hematology, Unité Hémopathies Lymphoïdes, AP-HP, F-94010, Créteil
| | - Laurence De Leval
- Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University
| | | | | | | | - Laurent Genestier
- Claude Bernard Lyon 1 University, ENS de Lyon, CNRS, UMR5308, INSERM U1111, CIRI, Centre International de Recherche en Infectiologie, Lymphoma Immunobiology Team (LIB), Equipe Labellisée Ligue Contre le Cancer, F-69007, Lyon, France; Hospices Civils de Lyon, Lyon
| | - Stefano Caruso
- Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil
| | - Philippe Gaulard
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil
| | - Olivier Hermine
- Université de Paris, Institut Imagine, Laboratory of Hematological Disorders, INSERM UMR1163, F-75015, Paris, France; Necker-Enfants Malades University Medical Center, AP-HP Clinical Hematology, F-75015, Paris
| | - Nicolas Ortonne
- Paris-Est Créteil University (UPEC), Institut Mondor de Recherche Biomédicale (IMRB), INSERM U955, F-94010, Créteil, France; Henri Mondor hospital, AP-HP, Department of Pathology, F-94010, Créteil.
| |
Collapse
|
2
|
Carty SA, Murga-Zamalloa CA, Wilcox RA. SOHO State of the Art Updates and Next Questions | New Pathways and New Targets in PTCL: Staying on Target. CLINICAL LYMPHOMA, MYELOMA & LEUKEMIA 2023; 23:561-574. [PMID: 37142534 PMCID: PMC10565700 DOI: 10.1016/j.clml.2023.04.007] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/16/2023] [Revised: 04/05/2023] [Accepted: 04/16/2023] [Indexed: 05/06/2023]
Abstract
While the peripheral T-cell lymphomas (PTCL) remain a therapeutic challenge, and increasingly account for a disproportionate number of lymphoma-related deaths, improved understanding of disease pathogenesis and classification, and the development of novel therapeutic agents over the past decade, all provide reasons for a more optimistic outlook in the next. Despite their genetic and molecular heterogeneity, many PTCL are dependent upon signaling input provided by antigen, costimulatory, and cytokine receptors. While gain-of-function alterations effecting these pathways are recurrently observed in many PTCL, more often than not, signaling remains ligand-and tumor microenvironment (TME)-dependent. Consequently, the TME and its constituents are increasingly recognized as "on target". Utilizing a "3 signal" model, we will review new-and old-therapeutic targets that are relevant for the more common nodal PTCL subtypes.
Collapse
Affiliation(s)
- Shannon A Carty
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI
| | | | - Ryan A Wilcox
- Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI.
| |
Collapse
|
3
|
Braun T, Schrader A. Education and Empowering Special Forces to Eradicate Secret Defectors: Immune System-Based Treatment Approaches for Mature T- and NK-Cell Malignancies. Cancers (Basel) 2023; 15:cancers15092532. [PMID: 37173999 PMCID: PMC10177197 DOI: 10.3390/cancers15092532] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2023] [Revised: 04/23/2023] [Accepted: 04/25/2023] [Indexed: 05/15/2023] Open
Abstract
Mature T- and NK-cell leukemia/lymphoma (MTCL/L) constitute a heterogeneous group of, currently, 30 distinct neoplastic entities that are overall rare, and all present with a challenging molecular markup. Thus, so far, the use of first-line cancer treatment modalities, including chemotherapies, achieve only limited clinical responses associated with discouraging prognoses. Recently, cancer immunotherapy has evolved rapidly, allowing us to help patients with, e.g., solid tumors and also relapsed/refractory B-cell malignancies to achieve durable clinical responses. In this review, we systematically unveiled the distinct immunotherapeutic approaches available, emphasizing the special impediments faced when trying to employ immune system defense mechanisms to target 'one of their own-gone mad'. We summarized the preclinical and clinical efforts made to employ the various platforms of cancer immunotherapies including antibody-drug conjugates, monoclonal as well as bispecific antibodies, immune-checkpoint blockades, and CAR T cell therapies. We emphasized the challenges to, but also the goals of, what needs to be done to achieve similar successes as seen for B-cell entities.
Collapse
Affiliation(s)
- Till Braun
- Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany
| | - Alexandra Schrader
- Department I of Internal Medicine, Center for Integrated Oncology, Aachen-Bonn-Cologne-Duesseldorf, Excellence Cluster for Cellular Stress Response and Aging-Associated Diseases, Center for Molecular Medicine Cologne, University of Cologne, 50937 Cologne, Germany
- Lymphoma Immuno Biology Team, Equipe Labellisée LIGUE 2023, Centre International de Recherche en Infectiologie, INSERM U1111-CNRS UMR5308, Faculté de Médecine Lyon-Sud, Hospices Civils de Lyon, Université Claude Bernard Lyon I-ENS de Lyon, 69921 Lyon, France
| |
Collapse
|
4
|
Mutations Affecting Genes in the Proximal T-Cell Receptor Signaling Pathway in Peripheral T-Cell Lymphoma. Cancers (Basel) 2022; 14:cancers14153716. [PMID: 35954378 PMCID: PMC9367541 DOI: 10.3390/cancers14153716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Revised: 07/22/2022] [Accepted: 07/22/2022] [Indexed: 12/04/2022] Open
Abstract
Simple Summary The advent of next-generation sequencing (NGS) has allowed rapid advances in genomic studies on the pathogenesis and biology of peripheral T-cell lymphoma (PTCL). Recurrent mutations and fusions in genes related to the proximal TCR signaling pathway have been identified and show an important pathogenic role in PTCL. In this review, we summarize the genomic alterations in TCR signaling identified in different subgroups of PTCL patients and the functional impact of these alterations on TCR signaling and downstream pathways. We also discuss novel agents that could target TCR-related mutations and may hold promise for improving the treatment of PTCL. Abstract Peripheral T-cell lymphoma (PTCL) comprises a heterogeneous group of mature T-cell malignancies. Recurrent activating mutations and fusions in genes related to the proximal TCR signaling pathway have been identified in preclinical and clinical studies. This review summarizes the genetic alterations affecting proximal TCR signaling identified from different subgroups of PTCL and the functional impact on TCR signaling and downstream pathways. These genetic abnormalities include mostly missense mutations, occasional indels, and gene fusions involving CD28, CARD11, the GTPase RHOA, the guanine nucleotide exchange factor VAV1, and kinases including FYN, ITK, PLCG1, PKCB, and PI3K subunits. Most of these aberrations are activating mutations that can potentially be targeted by inhibitors, some of which are being tested in clinical trials that are briefly outlined in this review. Finally, we focus on the molecular pathology of recently identified subgroups of PTCL-NOS and highlight the unique genetic profiles associated with PTCL-GATA3.
Collapse
|